Welcome to our dedicated page for Verastem SEC filings (Ticker: VSTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Verastem, Inc. filings document a Nasdaq-listed biopharmaceutical company with common stock trading under VSTM and a business focused on RAS/MAPK pathway-driven cancers. Its 8-K reports furnish corporate presentations, financial-result releases, strategic updates, clinical data disclosures, and Regulation FD materials for AVMAPKI FAKZYNJA CO-PACK, RAMP clinical programs, and VS-7375.
The company’s SEC records also cover capital-structure activity, including common stock and pre-funded warrant offerings, and proxy disclosures for board matters, executive compensation, equity awards, and shareholder voting. These filings frame Verastem’s commercialization, pipeline development, governance, financing, and public-company reporting obligations.
Verastem Inc. Schedule 13G/A (Amendment No. 5) reporting that Balyasny Asset Management and affiliated entities may be deemed to beneficially own 1,360,391 shares of Common Stock. The disclosure states this represents approximately 1.55% of the class based on 87,835,106 shares outstanding as of February 27, 2026.
The filing attributes the position to Balyasny Asset Management L.P., BAM GP LLC, Balyasny Asset Management Holdings, Dames GP LLC, and Dmitry Balyasny by virtue of management and control relationships. The 1,360,391 figure consists of 1,217,534 shares held by Atlas Diversified Master Fund, Ltd. and 142,857 shares issuable upon exercise of warrants; the warrants are subject to a 9.99% Beneficial Ownership Limitation.
Verastem, Inc. filed a current report stating that it has posted an updated corporate presentation on its website. The presentation is dated May 7, 2026 and is furnished as Exhibit 99.1. This Form 8-K is presented under Regulation FD, providing investors with access to the same information.
Verastem, Inc. reports first-quarter 2026 results, showing its transition to a commercial-stage oncology company but also emphasizing substantial doubt about its ability to continue as a going concern over the next twelve months.
The company generated $18.7 million in net product revenue from AVMAPKI FAKZYNJA CO-PACK in the United States, compared with no revenue a year earlier. Operating expenses rose to $63.6 million, driven mainly by $38.2 million in research and development and $22.3 million in selling, general and administrative costs.
Verastem recorded a net loss of $36.6 million, an improvement from a $52.1 million loss in the prior-year quarter, helped by a $9.3 million non-cash gain from changes in warrant liability fair value. Cash, cash equivalents, restricted cash and investments totaled about $181.9 million as of March 31, 2026, but management’s assessment highlights continued operating losses, significant cash use and dependence on future financings or revenues, leading to the disclosed going concern uncertainty.
Verastem, Inc. President and CEO Dan Paterson reported an open-market sale of 806 shares of common stock at $5.82 per share. After the transaction, he directly holds 612,113 shares of Verastem common stock.
The filing explains that the sale was made to satisfy statutory withholding requirements arising from the vesting of restricted stock units, indicating it was a tax-related transaction tied to equity compensation rather than a discretionary reduction of his overall stake.
Verastem, Inc. is asking stockholders to vote at its 2026 annual meeting on May 21, 2026, in Needham, Massachusetts. Holders of 87,842,899 common shares as of March 24, 2026 may vote.
Stockholders will elect three Class II directors, including two incumbents and new nominee Michael P. Bailey, and vote on four other proposals. These include approval of an Amended and Restated 2021 Equity Incentive Plan adding 12,000,000 shares, and an Amended and Restated 2018 Employee Stock Purchase Plan adding 5,000,000 shares. Verastem estimates total potential dilution from existing equity plans and the new share pool at 18.1%.
Investors are also asked to ratify Ernst & Young LLP as auditor for 2026 and approve an advisory say‑on‑pay vote for named executive officers. The Board unanimously recommends voting in favor of all proposals.
Verastem Inc received an Amendment No. 2 to Schedule 13G/A from The Vanguard Group reporting that, following an internal realignment, certain Vanguard subsidiaries will report beneficial ownership separately. The filing states amount beneficially owned: 0 and percent of class: 0%. The amendment cites SEC Release No. 34-39538 (January 12, 1998) as the basis for disaggregated reporting and is signed by Vanguard's Head of Global Fund Administration.
Calkins Daniel reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc.’s Chief Financial Officer Daniel Calkins received a grant of 57 shares of common stock on March 20, 2026 at a value of $5.74 per share. This was a compensation-related award, not an open-market purchase. Following the grant, he directly holds 121,327 common shares.
Verastem, Inc. filed a current report to let investors know it has posted an updated corporate presentation on its website. The presentation, dated March 4, 2026 and filed as Exhibit 99.1, is provided under Regulation FD to share the same information with all market participants.
Verastem, Inc. outlines a pivotal year transforming into a commercial-stage oncology company focused on RAS/MAPK pathway-driven cancers. The company markets AVMAPKI FAKZYNJA CO-PACK in the U.S., the first FDA-approved therapy specifically for KRAS‑mutated recurrent low‑grade serous ovarian cancer.
AVMAPKI FAKZYNJA CO-PACK received accelerated approval in May 2025, was commercially available within a week, and generated $30.9 million in net product revenue over its first seven months. A global Phase 3 confirmatory trial (RAMP 301) fully enrolled ahead of schedule and is intended to support full approval and a broader LGSOC label.
Beyond LGSOC, Verastem is advancing avutometinib plus defactinib in first-line pancreatic cancer (RAMP 205) and developing VS-7375, a selective oral KRAS G12D ON/OFF inhibitor licensed from GenFleet. VS-7375 is in U.S. Phase 1/2 trials and has FDA Fast Track designations in KRAS G12D-mutated pancreatic cancer.
Verastem, Inc. ownership update: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 3,536,000 shares of common stock, representing 5.30% of the class as of 12/31/2025. The filing states Armistice Capital exercises shared voting and dispositive power over these shares under its Investment Management Agreement; the Master Fund is the direct holder. The filing is a joint Schedule 13G signed on 02/17/2026.